January 24, 2022 11:05 AM ESTUpdated 11:15 AM

BeiGene/Novartis tout new PD-1 data; Novartis plans downsizing in Tokyo

ENDPOINTS

BeiGene and Novartis are continuing to build out data for its PD-1 inhibitor tislelizumab, and on Monday revealed its newest Phase III topline results. …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

BeiGene/Novartis tout new PD-1 data; Novartis plans downsizing in Tokyo

ENDPOINTS

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

CBER's deputy director departs as staff shakeup continues

Will CRISPR matter?

Teva launches Stelara biosimilar at 85% discount as wider field emerges

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

BeiGene/No­var­tis tout new PD-1 da­ta; No­var­tis plans down­siz­ing in Tokyo

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

BeiGene/Novartis tout new PD-1 data; Novartis plans downsizing in Tokyo